Koers Interpace Biosciences, Inc. Other OTC
Aandelen
IDXG
US46062X3035
Beheerde gezondheidszorg
Omzet 2022 | 31,84 mln. 29,78 mln. | Omzet 2023 | 40,21 mln. 37,61 mln. | Marktkapitalisatie | 4,69 mln. 4,39 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -22 mln. -20,58 mln. | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | 0,49 x |
Nettoschuld 2022 | 11,26 mln. 10,53 mln. | Nettoschuld 2023 | 7,69 mln. 7,2 mln. | EV/omzet 2023 | 0,31 x |
K/w-verhouding 2022 |
-0,2
x | K/w-verhouding 2023 |
6,03
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 72,42% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 01-12-20 |
Director of Finance/CFO | 32 | 01-06-19 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 01-02-22 |
Joseph Keegan
BRD | Director/Board Member | 71 | 01-01-16 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 01-09-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-15,06% | 5,53 mld. | |
+0,60% | 1,26 mld. |